Optex Biomedical
This article was originally published in The Gray Sheet
Executive Summary
Plans to resume operations following completion of initial public offering of 800,000 shares of common stock at $5 per share, according to a prospectus filed with the Securities and Exchange Commission. The Woodlands, Texas-based firm, which shut down in January due to lack of funds, plans to use the anticipated $3.2 mil. in net proceeds for marketing the firm's BioSentry continuous blood gas monitor system, as well as for R&D for future products, payment of certain obligations, working capital and general corporate purposes. From its inception in 1988 through 1993, Optex incurred a cumulative loss of $15.2 mil., and as of Dec. 31, 1993, the firm had $ 240,000 in cash.
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.